Medivir AB (STO:MVIR), a developer of innovative drugs with a focus on cancer where the unmet medical needs are high, announced on Thursday that new data from the phase I study of birinapant, in combination with pembrolizumab (Keytruda), will be presented during the American Society of Clinical Oncology annual meeting, which will take place during 31 May 2019 to 4 June 2019 in Chicago, US.

The abstract 2506, 'Determination of the recommended phase ll dose of birinapant in combination with pembrolizumab: Results from the dose-escalation phase of BPT 201', will be presented at an oral session on 2 June 2019 by Dr Russel J Schilder, Thomas Jefferson University, Sidney Kimmel Cancer Centre, Philadelphia, US.

Birinapant is being developed to enhance responses and extend survival, of patients with solid tumours, where existing treatments do not provide sufficient survival benefit, or where patients no longer have treatment options. Based on its unique design and mechanism, birinapant has the potential to enhance patients' responses in combination with other treatments. Medivir's initial focus is on developing birinapant in combination with an immuno-oncology agent.